Building upon this evidence, we have performed an unbiased, systematic, and comprehensive genome-wide discovery to identify a novel and robust gene signature (gene selection based on the significant correlation with BDNF and significant association with cancer pathology) that can predict tumor recurrence in patients with stage I, II, and III CRC. The gene discussed is BDNF; the disease is colorectal carcinoma.